Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
2026年 10月 23日
Read MoreZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
2026年 10月 21日
Read MoreZai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
2026年 10月 14日
Read MoreZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2026年 9月 29日
Read MoreZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
2026年 8月 17日
Read MoreZai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
2026年 8月 6日
Read MoreU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
2026年 8月 3日
Read More